基于SREBPs靶点中药对非酒精性脂肪性肝病大鼠治疗作用Meta分析*

目的本研究旨在通过Meta分析观察中药是否可以通过调控固醇调节元件结合蛋白（Sterol Regulatory Element Binding Proteins，SREBPS）相关靶点治疗非酒精性脂肪性肝病（Non-alcoholic fatty liver disease，NAFLD）。方法 本文通过中国知网、万方数据库、维普网、PubMed数据库、Embase数据库检索相关文献进行分析。结果 纳入18篇文献，Meta分析结果表明，与模型组大鼠相比，中药治疗组可以明显减少大鼠血清甘油三酯（TG）（P<0.000 1），总胆固醇（TC）（P<0.000 01），低密度脂蛋白（LDL-C）（P<0.000 01），ALT（丙氨酸氨基转移酶）（P<0.000 01），AST（天冬氨酸氨基转移酶）（P<0.000 01)，HOMA-IR（胰岛素抵抗指数）（P<0.000 01），抑制SREBP-1c mRNA（P<0.000 01），对高密度脂蛋白（HDL-C）（P=0.06）无明显作用。结论 本研究通过Meta分析发现中药可以通过调节SREBP-1c相关靶点降低NAFLD大鼠的血脂，改善其肝功能，进而治疗NAFLD，为指导临床用药和中药制剂的研发提供药理学依据。

Meta-analysis of the Therapeutic Effect of Chinese Medicine Based on SREBPs Target in Non-alcoholic Fatty Liver Rats

Objective The present study aimed to investigate whether Chinese medicine could treat non-alcoholic fatty liver disease(NAFLD) by regulating SREBPs related targets through Meta analysis. Methods This paper analyzed relevant literatures through China Knowledge Network, Wanfang database, Weipu.com, PubMed database and Embase database. Results 18 articles were included, Meta analysis showed that compared with model group, the Chinese medicine group could significantly reduce serum triglyceride(TG)(P<0.000 1), total cholesterol(TC)(P<0.000 01), low-density lipoprotein( LDL-C)(P<0.000 01), ALT(alanine aminotransferase)(P<0.000 01), AST(aspartate aminotransferase)(P<0.000 01), HOMA-I(insulin resistance index)(P<0.000 01), and inhibited SREBP-1c mRNA(P<0.000 01), while had no significant effect on high-density lipoprotein(HDL-C)(P=0.06). Conclusion This Meta analysis study found that Chinese medicine could reduce blood lipids, improve liver function and treat NAFLD in rat model by regulating SREBP-1c related targets, thus provide pharmacological basis for guiding the research and development of clinical drugs and traditional Chinese medicine preparations.